Did you like this article? Please share it.
With their biosensors, pharmaceutical industry can save 100 million CHF in the development of new drugs. No wonder the newly born spin-off of the Paul Scherrer Institute, InterAx Biotech AG, and their business concept won the SwissUpStart Challenge this year.
For the development of new drugs, pharmaceutical companies have to test about a dozen of substances on animals and humans to find the one that can reach the market. It is a capital-intensive process. InterAx Biotech found a way to enhance the quality of the drug candidates that enter clinical phases, reducing the failure rate and thus save effort and money. They develop biosensors enabling the discovery of functionally selective drugs with improved efficacy and reduced side effects for the largest class of human receptors (GPCRs).
On Thursday 20th October, after nine months of competition, InterAx was announced to be the winner of the SwissUpStart Challenge organized and hosted by the University of Applied Sciences and Arts Northwestern Switzerland FHNW in Brugg-Windisch in the Canton of Aargau. The jury evaluated the technology and its implementation, the market potential, the scalability and the ability of the team to convince a heterogeneous audience. The company’s plans for their win (20,000 CHF) are to attract new talents and to expand the team starting with a senior scientist with industry experience. The team is eager to continue its work, also as they are taking part in other challenges, such as the ZKB TECHNOPARK® Pioneer Award 2016.
PARK INNOVAARE congratulates InterAx’s team and wishes them best of luck for their future projects.